Medical management of pulmonary disease caused by Mycobacterium avium complex

被引：25

作者：

Iseman, MD ^{[1
]}

机构：

[1] Univ Colorado, Sch Med, Infect Dis Sect, Clin Mycobaceteriol Serv, Denver, CO 80262 USA

来源：

CLINICS IN CHEST MEDICINE | 2002年 / 23卷 / 03期

关键词：

D O I：

10.1016/S0272-5231(02)00023-0

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

The current medical therapy for Mycobacterium avium complex is controversial. American Thoracic Society recommendations advocate empiric therapy with drug susceptibility testing only for clarithromycin. At National Jewish, where vie mainly see cases complicated by treatment failure and drug intolerance, we use in vitro susceptibility testing and therapeutic drug monitoring to optimize efficacy and reduce toxicity.

引用

页码：633 / +

页数：10

共 40 条

[1]

AHN CH, 1986, AM REV RESPIR DIS, V134, P438

[2] Rifamycin-induced lupus syndrome [J].

Berning, SE ;

Iseman, MD .

LANCET, 1997, 349 (9064) :1521-1522

[3] Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease [J].

Brown, BA ;

Griffith, DE ;

Girard, W ;

Levin, J ;

Wallace, RJ .

CLINICAL INFECTIOUS DISEASES, 1997, 24 (05) :958-964

[4] Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection [J].

Chaisson, RE ;

Keiser, P ;

Pierce, M ;

Fessel, WJ ;

Ruskin, J ;

Lahart, C ;

Benson, CA ;

Meek, K ;

Siepman, N ;

Craft, JC .

AIDS, 1997, 11 (03) :311-317

[5] CLARITHROMYCIN THERAPY FOR BACTEREMIC MYCOBACTERIUM-AVIUM COMPLEX DISEASE - A RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING STUDY IN PATIENTS WITH AIDS [J].

CHAISSON, RE ;

BENSON, CA ;

DUBE, MP ;

HEIFETS, LB ;

KORVICK, JA ;

ELKIN, S ;

SMITH, T ;

CRAFT, JC ;

SATTLER, FR ;

STOOL, EW ;

MACGREGOR, RR ;

BUEHNER, T ;

WU, AW ;

BARNES, GL ;

BECKER, R ;

URBANSKI, P ;

RICHARDSON, W ;

HAFNER, R ;

DIXON, D ;

FEIGAL, DW ;

DELLERSON, M ;

GUPTA, S ;

HENRY, D ;

SCHLAGER, S .

ANNALS OF INTERNAL MEDICINE, 1994, 121 (12) :905-911

[6] CLARITHROMYCIN IN THE TREATMENT OF MYCOBACTERIUM-AVIUM LUNG INFECTIONS IN PATIENTS WITHOUT AIDS [J].

DAUTZENBERG, B ;

PIPERNO, D ;

DIOT, P ;

TRUFFOTPERNOT, C ;

CHAUVIN, JP .

CHEST, 1995, 107 (04) :1035-1040

[7] ACTIVITY OF CLARITHROMYCIN AGAINST MYCOBACTERIUM-AVIUM INFECTION IN PATIENTS WITH ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME - A CONTROLLED CLINICAL-TRIAL [J].

DAUTZENBERG, B ;

TRUFFOT, C ;

LEGRIS, S ;

MEYOHAS, MC ;

BERLIE, HC ;

MERCAT, A ;

CHEVRET, S ;

GROSSET, J .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (03) :564-569

[8]

DAVIDSON PT, 1981, REV INFECT DIS, V3, P1052

[9] ACTIVITY OF RIFABUTIN ALONE OR IN COMBINATION WITH CLOFAZIMINE OR ETHAMBUTOL OR BOTH AGAINST ACUTE AND CHRONIC EXPERIMENTAL MYCOBACTERIUM-INTRACELLULARE INFECTIONS [J].

GANGADHARAM, PRJ ;

PERUMAL, VK ;

JAIRAM, BT ;

RAO, PN ;

NGUYEN, AK ;

FARHI, DC ;

ISEMAN, MD .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1987, 136 (02) :329-333

[10] INVIVO ACTIVITY OF AMIKACIN ALONE OR IN COMBINATION WITH CLOFAZIMINE OR RIFABUTIN OR BOTH AGAINST ACUTE EXPERIMENTAL MYCOBACTERIUM-AVIUM COMPLEX INFECTIONS IN BEIGE MICE [J].

GANGADHARAM, PRJ ;

PERUMAL, VK ;

PODAPATI, NR ;

KESAVALU, L ;

ISEMAN, MD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (09) :1400-1403

← 1 2 3 4 →